These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31495502)

  • 1. Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again.
    Croft AJ; Ngo DTM; Sverdlov AL
    Heart Lung Circ; 2019 Oct; 28(10):1454-1456. PubMed ID: 31495502
    [No Abstract]   [Full Text] [Related]  

  • 2. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy.
    Jahangir E; Shah S; Shum K; Baxter C; Fitzpatrick JD; Cole J; Gilliland Y; Polin NM
    South Med J; 2015 Feb; 108(2):71-8. PubMed ID: 25688890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e84-e92. PubMed ID: 27755246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
    Elbl L; Hrstkova H; Tomaskova I; Michalek J
    Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
    Silber JH
    Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review.
    Lin KJ; Lengacher CA
    Oncol Nurs Forum; 2019 Sep; 46(5):E145-E158. PubMed ID: 31424455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?
    Suter TM; Meier B
    Ann Oncol; 2002 May; 13(5):647-9. PubMed ID: 12075731
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late Anthracycline-Related Cardiotoxicity in Low-Risk Breast Cancer Patients.
    Maestrini V; Cheang MH; Kotwinski P; Rosmini S; Lloyd G; Kellman P; Pennell DJ; Montgomery H; Moon JC; Manisty C
    J Am Coll Cardiol; 2017 May; 69(20):2573-2575. PubMed ID: 28521895
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
    Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
    Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
    Armenian S; Bhatia S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():3-12. PubMed ID: 30231396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
    Armenian SH
    Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of anthracycline cardiotoxicity].
    Rossetti R
    Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
    [No Abstract]   [Full Text] [Related]  

  • 18. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity.
    Jones RL; Miles DW
    Lancet Oncol; 2005 Feb; 6(2):67. PubMed ID: 15683815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.